Lomond Therapeutics Holdings, Inc. today announced the addition of two new investors, Yosemite Capital and QIA Investments, coincident with a second and third closing, respectively, and the raising of an additional $20 million private placement financing.

Lomond Therapeutics announced results from single ascending dose Phase 1 clinical studies of oral once-daily lonitoclax.

Lomond Therapeutics, a subsidiary of Eilean Therapeutics LLC, today announced an abstract related to the company's Lomonitinib, a highly potent and selective pan-FLT3/IRAK4 inhibitor that targets clinically relevant FLT3 mutations and putative escape pathways, has been accepted for a poster presentation at the upcoming American Society of Hematology (ASH) Annual Meeting.

Lomond Therapeutics, Inc. today announced the completion of a reverse merger transaction with Venetian-1 Acquisition Corp. and the closing of a $44 million private placement financing.

Lomond Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared Lomond’s Investigational New Drug (IND) application for a Phase 1 multicenter study evaluating the feasibility, safety, and efficacy of lonitoclax in patients with relapsed/refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and select low-grade lymphomas.